2026 Annual Meeting | Industry Therapeutic Update from UCB: Scientific exchange on new clinical and real-world evidence for FINTEPLA (fenfluramine) in Dravet and Lennox-Gastaut syndromes

Date Saturday 04/18/26

Time 11:45 AM - 12:45 PM CDT Add To Calendar

Location McCormick Place West | W471

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Topic(s) Epilepsy/Clinical Neurophysiology (EEG)

Learning Objectives How do long-term and real-world data inform our understanding of treatment outcomes in Dravet and Lennox-Gastaut syndromes?

This lunchtime program will feature a scientific exchange on new clinical and real-world evidence related to fenfluramine in Dravet and Lennox-Gastaut syndromes. Brief poster-style data presentations will be paired with expert commentary to contextualize findings for clinical practice. The program will also highlight real-world use of an updated refractory epilepsy screening tool to support identification of Lennox-Gastaut syndrome and conclude with an interactive Q&A.

OBJECTIVES
- Characterize the long-term tolerability and global functioning outcomes associated with fenfluramine in patients with Dravet and Lennox-Gastaut syndromes
- Describe the association between fenfluramine and everyday executive functioning in adults with Lennox-Gastaut syndrome
- Review real-world healthcare resource utilization and antiseizure medication patterns in patients with Lennox-Gastaut syndrome treated with fenfluramine
- Explore the role of an updated refractory epilepsy screening tool in identifying Lennox-Gastaut syndrome in real-world practice

CME Available No CME available

Program Materials Program Evaluations

Event Timeline
11:45 AM - 12:45 PM CDT	Speaker	Industry Therapeutic Update from UCB: Scientific exchange on new clinical and real-world evidence for FINTEPLA (fenfluramine) in Dravet and Lennox-Gastaut syndromes

Faculty Disclosures
David E. Burdette, MD	Dr. Burdette has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Jazz Pharmaceuticals. Dr. Burdette has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Catalyst. Dr. Burdette has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Jazz Pharmaceuticals. Dr. Burdette has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for SK Life pharmaceuticals. Dr. Burdette has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for NeuroPace. Dr. Burdette has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Burdette has received research support from Longboard. The institution of Dr. Burdette has received research support from NeuroPace.
Amelie Lothe, PhD	Dr. Lothe has received personal compensation for serving as an employee of UCB. Dr. Lothe has or had stock in UCB.
Jaya S. Khushalani, MD, PhD	Dr. Khushalani has received personal compensation for serving as an employee of UCB. Dr. Khushalani has or had stock in UCB.
Heidi L. Henninger, MD, FAAN	Dr. Henninger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB.